EC challenges Belgium over laboratory practices:
This article was originally published in Clinica
The European Commission has asked Belgium to change the conditions for reimbursement of medical analyses. The Commission has served Belgium with a Reasoned Opinion, asking it to modify certain provisions of Royal Decree 143 of December 30 1982, whereby non-Belgian laboratories are at a disadvantage compared to certain Belgian professionals. Only laboratories which meet the "restrictive conditions imposed by this Royal Decree", the Commission stated last week, may provide services eligible for reimbursement by the sickness insurance scheme, thus discouraging people covered by this from using laboratories which do not meet these conditions, in contravention of Article 43 of the EC Treaty on the freedom of establishment. Belgium has two months to respond, after which time the Commission may refer the case to the Court of Justice.
You may also be interested in...
After two Indian vaccine makers, Serum Institute of India and Cadila Healthcare joined the fight against COVID-19, Bharat Biotech may follow suit. Others like Hilleman have decided against it for the moment while Panacea Biotech is weighing the pros and cons of developing a SARS-CoV-2 vaccine after a sour experience with H1N1.
South Korea’s HLB has begun a new growth phase by taking over US-based clinical stage biotech firm Immunomic Therapeutics. Through the acquisition, it is poised to add new pipeline assets including a Phase II vaccine therapy for glioblastoma and proprietary lysosomal targeting technology.
Less-invasive technologies to treat benign prostatic hyperplasia are fast becoming viable alternatives to medication and surgery. Here's what one researcher in the area, Steven Raman, had to say about the new options.